Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant

Pharmacotherapy

Volumn 28, Issue 7, 2008, Pages 939-944

  Abdulhamid, Ibrahim ^a   Wise, Terri L ^b   Andrews, Stephanie ^b   Biglin, Kevin ^a   Lehr, Victoria Tutag ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Adverse drug reactions; Aminoglycosides; Infants; Inhaled

Indexed keywords

ANTIBIOTIC AGENT; TOBRAMYCIN;

ARTICLE; ASSISTED VENTILATION; AUTOPSY; BLOOD CULTURE; BRONCHOPNEUMONIA; CASE REPORT; CAUSE OF DEATH; CHILD DEATH; CONGENITAL MALFORMATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; INFANT; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LUNG HYPOPLASIA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEWBORN INTENSIVE CARE; PREMATURITY; PSEUDOMONAS AERUGINOSA; SEPSIS; STENOTROPHOMONAS MALTOPHILIA; TISSUE SECTION; TRACHEOSTOMY; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; FATAL OUTCOME; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PNEUMONIA, BACTERIAL; TOBRAMYCIN;

EID: 45749156421     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.7.939     Document Type: Article

References (22)

1. Proper CG, Walson PD, Jones J. Technical report: precaution regarding the use of aerosolized antibiotics. Pediatrics 2000;106:E89.
2. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
3. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-26.
4. Rosenfeld M, Gibson R, McNamera S, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001;139:572-7.
5. Lobue P. Inhaled tobramycin: not just for cystic fibrosis anymore? Chest 2005;127:1098-101.
6. Couch L. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001;120:114S-7S.
7. Edson R, Brey R, McDonald T, Terrell C, McCarthy J, Thibert J. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004;79:1185-91.
8. Cannella C, Wilkinson ST. Acute renal lailure associated with inhaled tobramycin. Am J Health-Syst Pharm 2006;63:1858-61.
9. Kahler D, Schowengerdt K, Frickler F, Mansfield M, Visner G, Faro A. Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy 2003;23:543-5.
10. Ahya V, Doyle A, Mendez J, et al. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005;24:932-5.
11. Hoffman I, Rubin B, Iskander S, Schechter M, Nagaraj S, Bitzan M. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375-7.
12. Izquierdo M, Gomez-Alamillo C, Ortiz F, et al. Acute renal failure associated with use of inhaled tobramycin lor treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol 2006;66:464-7.
13. Patatanian L. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Pediatr Infect Dis J 2006;25:276-8.
14. Bentur Y, Hummel D, Roifman CM, Giesbrecht E, Koren G. Interpretation of excessive levels of inhaled tobramycin. Ther Drug Monit 1989;11:109-10.
15. Elidemir O, Maciejewski SR, Oermann CM. Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin. Pediatr Pulmonol 2000;29:43-5.
16. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998;26:31-9.
17. MacIntyre NR, Silver RM, Miller CW Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985;13:81-4.
18. Fink JB. Aerosol delivery to ventilated inlant and pediatric patients. Respir Care 2004;49:653-65.
19. Fiel SB, Fuchs HJ, Johnson C, Gonda I, Clark AR. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. Chest 1995;108:153-6.
20. Coates AL, MacNeish CF, Meisner D, et al. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997;111:1206-12.
21. de Hoog M, Monton JW, van den Anker JN. Vancomycin. Clin Pharmacokinet 2004;43:417-80.
22. Jarrett RV, Marinkovich GA, Gayle EL, et al. Individualized vancomycin dosage and dosing interval in preterm inlants. Pediatr Infect Dis J 1993;12:156-7.